Sight Sciences, Inc. SGHT
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Sight Sciences, Inc. (SGHT) is a healthcare company listed in the US with a market value of about $602M. In the twelve months to September 30, 2026 it had revenue of $88M and net income of -$28M, a net margin of -32.1%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 23% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.
About Sight Sciences
Sight Sciences is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $28M in 2020 to $77M in 2025, growth of about 22.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 19% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $88M | $77M | $80M | $81M | $71M | $49M | $28M |
| Net income | -$28M | -$38M | -$52M | -$56M | -$86M | -$63M | -$35M |
| Free cash flow | -$17M | -$30M | -$23M | -$48M | -$77M | -$53M | -$33M |
| EPS (diluted) | $-0.52 | $-0.74 | $-1.03 | $-1.14 | $-1.80 | $-2.36 | $-3.71 |
| Net margin | -32.1% | -49.7% | -64.5% | -68.5% | -120.9% | -128.6% | -125.5% |
| ROIC | — | -28.0% | -31.2% | -29.1% | -34.0% | -15.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $12.25, 13% above the current price; targets range from $10.00 to $14.00; the consensus rating is “Buy”; expected EPS is $-0.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Sight Sciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sight Sciences pay a dividend?
Not currently.
Is Sight Sciences a good stock to buy?
We do not give buy or sell advice. Sight Sciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.